ASCO: Bristol Myers Squibb, awaiting Opdivo-Yervoy approval, trumpets 3-year lung cancer survival win

13th May 2020 Uncategorised 0

Just days away from an FDA decision that could finally bring Bristol Myers Squibb’s Opdivo to previously untreated non-small cell lung cancer patients, the company’s Opdivo-Yervoy combo has put up positive three-year data.

More: ASCO: Bristol Myers Squibb, awaiting Opdivo-Yervoy approval, trumpets 3-year lung cancer survival win
Source: fierce